BRIEF published on 08/14/2025 at 07:05, 11 months 23 days ago Relief Therapeutics Releases 2025 Half-Year Report Relief Therapeutics RLF-TD011 RLF-OD032 2025 Half-Year Report NeuroX Partnership
PRESS RELEASE published on 08/14/2025 at 07:00, 11 months 23 days ago Relief Therapeutics Publishes 2025 Half-Year Report Relief Therapeutics published its 2025 half-year report, highlighting progress in pipeline candidates for rare diseases and financial status. Corporate update includes advances in wound care and liquid formulation for phenylketonuria Financial Status Relief Therapeutics Rare Diseases 2025 Half-Year Report Pipeline Candidates
BRIEF published on 08/11/2025 at 07:05, 11 months 26 days ago Relief Therapeutics Advances 2025 Half-Year Report Publication Biopharmaceutical Company Relief Therapeutics Innovative Treatments Geneva Half-Year Report 2025
PRESS RELEASE published on 08/11/2025 at 07:00, 11 months 26 days ago Relief Therapeutics Advances Publication of 2025 Half-Year Report Relief Therapeutics advances publication of its 2025 half-year report from August 27 to August 14, 2025, indicating completion ahead of schedule. Company to provide shareholder update and financial statements Biopharmaceutical Relief Therapeutics Publication Innovative Treatment Options 2025 Half-Year Report
BRIEF published on 07/29/2025 at 07:05, 1 year ago Relief Therapeutics and NeuroX to Merge, Expanding AI Health Tech SIX Swiss Exchange Mergers & Acquisitions Neurological Diseases AI Health Tech MindMaze
PRESS RELEASE published on 07/29/2025 at 07:00, 1 year ago Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze Relief Therapeutics to merge with NeuroX, successor to MindMaze, creating a SIX-listed, AI-driven health tech company. Transaction expected to close in Q4 2025 Business Combination Relief Therapeutics MindMaze NeuroX AI-driven Health Tech
BRIEF published on 06/20/2025 at 07:05, 1 year 1 month ago Relief Therapeutics Faces FDA Setback for RLF-TD011 QIDP Designation RLF-TD011 Orphan Drug FDA Response Epidermolysis Bullosa QIDP Designation
PRESS RELEASE published on 06/20/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
BRIEF published on 06/12/2025 at 11:05, 1 year 1 month ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
PRESS RELEASE published on 06/12/2025 at 11:00, 1 year 1 month ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
Published on 08/07/2026 at 00:45, 6 hours 12 minutes ago NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 7 hours 42 minutes ago LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 8 hours 42 minutes ago Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
Published on 08/06/2026 at 22:05, 8 hours 52 minutes ago Innodata Reports Record Second Quarter 2026 Results
Published on 08/06/2026 at 22:00, 8 hours 57 minutes ago Gold Terra Announces Closing of Second Tranche of the C$10.8M LIFE
Published on 08/07/2026 at 06:30, 27 minutes ago Avolta acquires majority stake in Penha Duty Free Group
Published on 08/07/2026 at 06:30, 27 minutes ago Mobimo Holding AG: Mobimo with strong operational performance in the first half of 2026
Published on 08/06/2026 at 22:15, 8 hours 42 minutes ago BIRKENSTOCK SEEKS TO FILL VACANCY IN THE BOARD OF DIRECTORS WITH AN INDEPENDENT DIRECTOR, FOLLOWING ALEXANDRE ARNAULT'S RESIGNATION DUE TO PROFESSIONAL COMMITTMENTS
Published on 08/06/2026 at 21:45, 9 hours 12 minutes ago FP Markets Analysis: Japanese Yen at a Crossroads as Markets Weigh Next Move
Published on 08/06/2026 at 18:26, 12 hours 31 minutes ago Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 17:45, 13 hours 12 minutes ago Declaration of voting rights at the end of July 2026
Published on 08/06/2026 at 17:35, 13 hours 22 minutes ago Groupe des Assurances du Crédit Mutuel (GACM)’s Solvency II ratio was 227% as of June 30, 2026
Published on 08/06/2026 at 17:35, 13 hours 22 minutes ago Availability of the financial statements of Groupe des Assurances du Crédit Mutuel for the first half of 2026
